Cingulate (CING) EVP/CMO Matthew Brams Receives Stock Award

What Happened Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc. (CING), received two derivative awards on 2026-07-16 totaling 80,000 shares (53,600 and 26,400). The reported acquisition price is $0.00, indicating these are compensation awards (derivative securities) rather than an open-market purchase or sale. This is an award/grant transaction, not an immediate cash purchase or sale.

Key Details

• Transaction date(s) and price: 2026-07-16; 53,600 and 26,400 shares reported at $0.00 (derivative awards).
• Total awarded: 80,000 derivative shares.
• Filing date: Form 4 filed 2026-07-20 (the filing shows the reporting date and transaction date; no late-filing/timeliness flag is shown in the filing).
• Shares owned after transaction: Not disclosed in the filing.
• Notable footnotes:
  • Vesting: 25% vests on March 31, 2027; remaining shares vest in substantially equal monthly installments over the 36 months following that date. (F1)
  • Exercisability: Vested option(s) become exercisable only if the issuer’s NDA for CTx‑1301 is approved by the FDA during 2027. (F2)
  • Termination condition: If the NDA is not approved in 2027, the option (including any vested portion) will terminate. (F3)
• No 10b5-1 plan, tax-withholding disposition, or immediate cashless exercise/sale is indicated in the filing.

Context These are derivative compensation awards tied to regulatory milestones (FDA approval of the NDA for CTx‑1301 in 2027). Because exercisability and continued validity of the awards depend on that approval, their value is contingent on a specific event rather than being immediately liquid or tradable. As a grant rather than a market purchase, this transaction reflects compensation structure and incentive alignment rather than a direct insider bet on the open market.